Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)

The summary for the Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33): This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development and validation of technologies that address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. Applications must include preliminary data sufficient to justify the feasibility of the proposed technology, but may still require additional development to reach a generally useful level of functionality for cancer-related research applications. The overall goal is to support the development of highly innovative technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or samples derived from those biospecimens for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to potentially accelerate and/or enhance research in cancer biology, early detection, screening, clinical diagnosis, treatment, epidemiology, and cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Federal Grant Title:	Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-CA-15-005
Type of Funding:	Grant
CFDA Numbers:	93.394
CFDA Descriptions:	Cancer Detection and Diagnosis Research
Current Application Deadline:	Sep 22, 2015
Original Application Deadline:	Sep 22, 2015
Posted Date:	Jan 8, 2015
Creation Date:	Jan 8, 2015
Archive Date:	Oct 23, 2015
Total Program Funding:	$800,000
Maximum Federal Grant Award:	$300,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	2
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
For profit organizations other than small businesses
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
County governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
Private institutions of higher education
Independent school districts
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
City or township governments
Public housing authorities/Indian housing authorities
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-005.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Bio...; • Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required); • Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 ...; • Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer...; • Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatme...; • Image-Guided Cancer Interventions (STTR [R41/R42]); • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44); • In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health: • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...; • Immune Tolerance Network (UM1 Clinical Trial Required); • Coordinating Center for National Resource Network for the Study of Human Auditory and Vest...; • National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Cl...; • Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Interven...